Who Paid My Doc
Andrew Windsperger
Urology Sartell, MN Medical Doctor
NPI 1124280425 CMS profile 1107336
2351 Connecticut Ave S, Suite 200, Sartell, MN 56377
General payments
$23,658
Research payments
$2,088
Ownership & investment interest
$0
Research they led as principal investigator
$202,132
Through program year 2025, Andrew Windsperger of Sartell, MN is reported in the CMS Open Payments database as having received $23,658 across 39 general payments and $2,088 in research payments paid to them. Separately, studies naming them as principal investigator received $202,132 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $0 across 3 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,002 | 7 | |
| 2024 | General | $216 | 6 | |
| 2023 | General | $156 | 5 | |
| 2023 | Research | $2,088 | 3 | |
| 2022 | General | $14,091 | 4 | |
| 2021 | General | $5,089 | 9 | |
| 2020 | General | $5 | 3 | |
| 2019 | General | $100 | 5 | |
| 2025 | Ownership | $0 | 1 | |
| 2024 | Ownership | $0 | 1 | |
| 2023 | Ownership | $0 | 1 |
Beside peers
- Andrew Windsperger
- Urology median
- Middle half of Urology
- National median
In program year 2025, general payments to Andrew Windsperger were reported at $4,002. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.
Show as a table
| Year | Andrew Windsperger | Urology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $100 | $480 | $147–$1,201 | $163 |
| 2020 | $5 | $246 | $87–$645 | $114 |
| 2021 | $5,089 | $358 | $111–$1,000 | $132 |
| 2022 | $14,091 | $476 | $143–$1,263 | $149 |
| 2023 | $156 | $560 | $168–$1,461 | $160 |
| 2024 | $216 | $563 | $170–$1,464 | $164 |
| 2025 | $4,002 | $629 | $190–$1,620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
3,359
Drug cost
$505,315
Branded share of claims
36.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 389 | $315,408 | |
| Gemtesa Vibegron | Brand | 46 | $50,751 | |
| Elmiron Pentosan Polysulfate Sodium | Brand | 26 | $25,782 | |
| Tamsulosin Hcl | Generic | 614 | $13,736 | |
| Solifenacin Succinate | Generic | 245 | $11,679 | |
| Mirabegron Er Mirabegron | Brand | 16 | $11,621 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 250 | $8,741 | |
| Fosfomycin Tromethamine | Generic | 17 | $8,146 | |
| Fesoterodine Fumarate Er Fesoterodine Fumarate | Brand | 63 | $6,186 | |
| Dutasteride | Generic | 166 | $5,156 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 92 billing codesPaid by Medicare
$128,126
Medicare patients
488
Services billed
9,070
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 46% | |
| Chronic kidney disease | 36% | |
| Diabetes | 32% | |
| Ischemic heart disease | 31% | |
| Cancer | 30% | |
| Depression | 28% | |
| Atrial fibrillation | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
42 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urology in Minnesota
Related records
Urology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Urology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.